This is a PhD project of Vivienne Moxham-Hall (supervised by Professor Alison Ritter and Dr Caitlin Hughes) investigating the utility of indexes as a measure of drug policy.
This is the PhD project of Ms Shann Hulme.
National and international evidence indicates that the non-medical use of pharmaceutical drugs is increasing, along with the associated health, social and economic harms.
Over the past few years, there has been a significant increase in the number of seizures and unintentional overdose fatalities related to illicit synthetic opioids in multiple states across the U.S.
This project attempts to understand the global epidemiology of infectious disease among prisoners in all countries.
This project is an international collaboration to assess the nature and extent of health outcomes from drug cryptomarkets, globally and specifically for Australians.
Cannabis remains one of the most commonly used psychoactive substances in the United States, and current epidemiological studies indicate broadening acceptability. This aim of this project is to decrease the burden of psychoactive substance use in the US.
To reduce alcohol related harms, the World Health Organisation recommends regulating the sale and supply of alcohol, including limiting the number of premises selling alcohol as well as the hours during which alcohol can be sold.
This project will review the evidence for the medicinal use of cannabis and cannabinoid products for a number of key medical conditions.
Changes to the status of cannabis, ranging from legalisation through to tougher enforcement of prohibition are frequently posed. To date, the debate has centred on arguments associated with liberty and harm, but not on economic analyses.
It has been argued that the increased influence of conservative advocacy groups and the impact of the political social conservatism of ‘The Howard Years’ has led to a conservative shift in Australian drug policy, away from harm minimisation and towards a zero tolerance model (Mendes, 2001,